Hydroxychloroquine News and Research

RSS

Australian COVID-19 prevention trial begins for frontline and allied healthcare workers

COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.

19 May 2020

The use of rheumatoid arthritis drug sarilumab in severe COVID-19 pneumonia

A new study published on the preprint server medRxiv* in May 2020 reports the beneficial effects of the monoclonal antibody sarilumab in severe COVID-19 pneumonia.

19 May 2020

Modified clinical trial design to meet urgent community needs during COVID-19 pandemic

A new paper published online in the Annals of the American Thoracic Society describes a nimble, pragmatic and rigorous multicenter clinical trial design to meet urgent community needs in the face of the COVID-19 pandemic.

19 May 2020

ECMO machine can be useful for treating critically ill COVID-19 patients

When COVID-19 patients are critically ill, the biggest threat to their lives is lung dysfunction. If their lungs don't work, their blood can't circulate enough oxygen to the brain, the liver and other organs.

18 May 2020

COVID-19 clinical trials show positive early results, says GlobalData

With the number of COVID-19 cases and deaths increasing with each passing day, the need for a therapeutic or a vaccine for the pandemic intensifies.

18 May 2020

COVID-19’s adverse impact on the cardiovascular system

COVID-19 can cause serious cardiovascular complications including heart failure, heart attacks and blood clots that can lead to strokes, emergency medicine doctors report in a new scientific paper.

15 May 2020

Chasing the elusive dream of a COVID cure

Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.

15 May 2020

NIH begins clinical study to evaluate hydroxychloroquine and azithromycin for COVID-19

A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19).

14 May 2020

ACTG initiates clinical trial to evaluate treatment for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2).

14 May 2020

Anti-inflammatory drug may improve respiratory function in some severe COVID-19 cases

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients with severe coronavirus disease 2019 (COVID-19).

14 May 2020

Lessons for COVID-19 from 2009 H1N1

The world has experienced many outbreaks of viral diseases. Over the past two decades, we have also seen the emergence of zoonotic human respiratory coronaviruses with pandemic potential.

13 May 2020

Could JAK blockers help treat COVID-19?

A new study published in the journal Science Immunology in May 2020 reports that compounds that safely inhibit the JAK protein could be useful in treating COVID-19.

12 May 2020

A 'multi-omics' approach to the development of drugs against COVID-19

A new study published on the preprint server medRxiv* in May 2020 reports a multi-omics approach that could make it easier to develop drugs that are effective against COVID-19.

12 May 2020

Clinical trial to test the efficacy of defibrotide medicine for reducing COVID-19 death rate

The Neurosciences Institute, mixed centre of the Spanish National Research Council and the Miguel Hernández University of Elche, have collaborated on the first clinical trial conducted in the world to test whether the defibrotide medicine, which has already been authorized to treat a severe obstruction of the hepatic sinusoidal veins of people who have undergone a bone marrow transplant, can be used as therapy against COVID-19.

12 May 2020

Hydroxychloroquine is not effective against COVID-19, extensive U.S. study shows

Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.

11 May 2020

Clinical trial launched to evaluate experimental COVID-19 therapies

Clinical leaders from the University of Kentucky's Markey Cancer Center, College of Medicine and College of Pharmacy have launched a clinical trial for experimental therapies to treat patients infected with COVID-19.

11 May 2020

Experts advise not to make COVID-19 crisis worse by rushing for cures

People have died from overdoses of unproven cures in past pandemics. In an editorial published today in Australian Prescriber, Associate Professor Darren Roberts from St Vincent’s Hospital in Sydney and Dr Alexandra Bennett from the NSW Therapeutic Advisory Group advise we should not make the current COVID-19 crisis worse by using medicines based on inadequate evidence.

11 May 2020

Perspective: Existing drugs could be repurposed for COVID-19 patients

Given the rapid spread of COVID-19 and its relatively high mortality, filling the gap for coronavirus-specific drugs is urgent.

9 May 2020

KHN’s ‘What the Health?’: Blowing the whistle on Trump team’s COVID policies

Those working inside the Trump administration are getting so frustrated with the response to the COVID-19 pandemic that they are going public.

8 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020